Short answer
After a pathogenic or likely pathogenic germline RET variant is identified, MEN2 follow-up should split into two practical tracks. One track is targeted family testing for relatives who may carry the known variant. The other is surveillance and specialist planning for the person who has the variant, including variant-specific thyroid, pheochromocytoma, and parathyroid questions. A family letter, genetics visit, and endocrine plan help keep those tracks from getting mixed up.
Separate testing from surveillance
Family testing asks, "Does this relative have the known RET family variant?" Surveillance asks, "What medical monitoring or prevention plan is appropriate for someone who has it?" Those questions often happen close together, but they are not the same decision.
| Situation | Main question | Best next guide |
|---|---|---|
| Known pathogenic family RET variant | Which relatives need targeted testing? | MEN2 family variant testing |
| Child at risk | When should testing and endocrine follow-up happen? | RET cascade testing for children |
| Positive germline RET result | What surveillance plan is tied to this exact variant? | MEN2 surveillance after positive RET testing |
| Calcitonin follow-up | Is the lab result being interpreted inside a MEN2-aware plan? | RET calcitonin follow-up |
| Relatives need a note | What exact variant information should be shared? | RET family letter questions |
Family pathway
For relatives, the clearest testing usually targets the exact known family RET variant rather than ordering a broad test without context. GeneReviews describes RET testing for at-risk relatives once a germline RET pathogenic variant has been identified in the family. A genetics professional can help decide which relatives are at risk, how to document the family variant, and how to handle children, pregnancy planning, privacy, and relatives who do not want testing.
Surveillance pathway
For someone who has the variant, follow-up should move from "what does the report say?" to "what is the variant-specific care plan?" MEN2 surveillance can involve calcitonin, thyroid planning, pheochromocytoma screening, calcium or parathyroid evaluation, and specialist timing. The exact RET variant, age, clinical findings, and family context matter.
Questions to ask
- Has the family's exact RET variant been documented in a clinical germline report?
- Which relatives are at risk, and which ones need targeted testing rather than broad screening?
- For children, who is coordinating genetics and pediatric endocrine follow-up?
- For a positive relative, what surveillance starts now and what depends on age or variant?
- Does the family letter give enough information for relatives to request the right test?
When follow-up matters more
Follow-up matters more when a hereditary tumor result could change who in the family should be tested, when tumor-only and germline questions are still mixed together, or when a specialist plan should decide surveillance timing rather than a single lab result. Genetics counseling helps keep the finding tied to the actual family question.
FAQ
What is the difference between family testing and surveillance?
Family testing asks who has the known RET variant. Surveillance asks what medical monitoring or prevention plan a positive person needs.
Who usually needs targeted family testing?
Relatives at risk for the known familial RET variant usually need targeted testing rather than a broad screen.
Why do children need special timing?
MEN2 timing can be age- and variant-specific, so pediatric genetics and endocrine planning matter.
Does a negative relative still need follow-up?
If the family variant is known and the relative tests negative for that exact variant, surveillance usually changes, but the family plan should still be confirmed by the specialist.
Should the family letter include the exact variant?
Yes. The exact variant is what helps relatives request the right targeted test.
What if the result is uncertain or tumor-only?
Uncertain or tumor-only findings should not be treated as a finished family testing plan without genetics review.
Related guides: RET result follow-up roadmap, RET codon and variant comparison guide, RET negative family variant testing interpretation, and RET prenatal and childhood testing questions.